Loading...
Market
Which Alzheimer's drug will lead the market share in China by end of 2025?
2
Eli Lilly•China•National Medical Products Administration•Eisai•Biogen•Leqembi•United States•Japan•United Kingdom•South Korea
Resolution / Starting Odds
Donanemab leads • 25%
Leqembi leads • 25%
Both have equal share • 25%
Other treatments lead • 25%
Market research reports and sales data
Story
Eli Lilly's Donanemab Approved in China for Early Alzheimer's Treatment, Following Eisai and Biogen's January Approval
Dec 18, 2024, 01:56 AM
Eli Lilly's Alzheimer’s treatment, donanemab, has received approval from China's National Medical Products Administration for use in patients with early symptomatic Alzheimer's disease. This approval offers a new option for patients in China following the earlier approval of Eisai and Biogen's Leqembi in January. Donanemab has previously been authorized in the United States, Japan, and the United Kingdom, expanding its availability for those affected by the disease. The approval comes as a joint research team from South Korea and the U.S. has revealed insights into the mechanism by which tau proteins, linked to Alzheimer's, are removed from the brain.
View original story
Similar markets
Kisunla™ • 33%
Leqembi • 33%
Other/new drugs • 33%
DDL-920 • 25%
Aduhelm • 25%
Leqembi • 25%
Other • 25%
Kisunla™ > Leqembi • 25%
Leqembi > Kisunla™ • 25%
Kisunla™ and Leqembi have equal market share • 25%
Other treatments lead • 25%
Kisunla > 50% • 25%
Kisunla 30-50% • 25%
Kisunla 10-30% • 25%
Kisunla < 10% • 25%
Leader • 25%
Top 3 • 25%
Top 5 • 25%
Not in Top 5 • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Company A • 25%
Company B • 25%
Company C • 25%
Other • 25%
PrecivityAD2™ dominates (>50%) • 25%
Sunbird Bio dominates (>50%) • 25%
Both share equally (~50% each) • 25%
Other diagnostic tests dominate • 25%
Less than 10% • 25%
10% - 20% • 25%
20% - 30% • 25%
More than 30% • 25%
Below 10% • 33%
10-20% • 33%
Above 20% • 33%
Novo Nordisk • 34%
Eli Lilly • 33%
Other • 33%
Lecanemab • 25%
Aducanumab • 25%
Another new drug • 25%
No approval • 25%